Serina Therapeutics Q1 net loss $4.8M; cash runway through Q3 2025

Serina Therapeutics, Inc.

2025-Q1 EPS reported -$0.49

Net loss attributable to Serina of $4.8M ($0.49/share) vs $15.0M ($5.38/share) in Q1 2024.
Cash and cash equivalents $4.3M at March 31, 2025; plus $5M April private placement extends runway through Q3 2025.
On track to dose first patient in Phase 1b trial of SER-252 for advanced Parkinson's in Q4 2025.
Secured $15M in equity financing since late 2024, including $10M from JuvVentures and $5M private placement.
Appointed Karen J. Wilson and Dr. Jay Venkatesan to the Board; POZ-lipid data showed no antibody response in rats.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.